Lastafry

Latanoprost, the active ingredient in Lastafry, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It lowers intraocular pressure and is indicated for open-angle glaucoma and ocular hypertension. GNH USA supplies Lastafry as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost, a prostaglandin analog, is used to lower intraocular pressure in glaucoma and ocular hypertension.

Open-angle glaucoma: reduces intraocular pressure to help prevent optic nerve damage. Ocular hypertension: lowers pressure to reduce the risk of developing glaucoma. Elevated intraocular pressure: provides sustained pressure reduction when other therapies are insufficient.

Latanoprost may cause ocular and systemic adverse reactions; most are mild and reversible.

Common Side Effects: - Eye redness or hyperemia. - Increased eyelash growth and length. - Darkening of the iris color. - Eye irritation or foreign‑body sensation. - Blurred vision. - Periocular skin hyperpigmentation.

Serious or Rare Side Effects: - Severe intraocular inflammation (uveitis) or iritis. - Allergic reactions such as contact dermatitis or angioedema. - Sudden loss of vision or macular edema. - Persistent ocular pain or photophobia.

Before using Lastafry, consider the following safety measures.

Pregnancy: safety not established; avoid use unless benefits outweigh risks. Breastfeeding: unknown safety; discuss with a healthcare professional. Active ocular infection: contraindicated until infection resolves. Regular IOP monitoring: schedule periodic eye‑pressure checks to assess effectiveness. Avoid cross‑contamination: do not share the bottle or touch the tip with fingers. Store at room temperature: keep in the original container, protect from light and moisture.

Latanoprost can interact with other ocular or systemic agents; awareness of potential interactions helps maintain efficacy and safety.

Major Interactions (Avoid): - Concurrent use of other prostaglandin analog eye drops may cause additive ocular effects. - Non‑steroidal anti‑inflammatory eye drops can reduce Latanoprost's IOP‑lowering effect. - Systemic carbonic anhydrase inhibitors may alter aqueous humor dynamics.

Moderate Interactions (Monitor Closely):\n- Beta‑blocker eye drops: additive IOP reduction may require monitoring. - Alpha‑agonist eye drops: combined therapy may increase risk of ocular irritation. - Systemic NSAIDs: may affect ocular surface tolerance.